^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CBT101

    i
    Associations
    News

    Trials

    Company:
    CHA Bio & Diostech
    Drug class:
    NK cell stimulant, Cell replacement
    Related drugs:
    Associations
    News

    Trials

    Apply
    APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) (NCT03175224)
    Phase 2
    Apollomics Inc.
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    09/27/2017
    Primary completion :
    03/30/2026
    Completion :
    11/30/2026
    HGF • PTPRZ1
    |
    EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion
    |
    bozitinib (APL-101) • CBT101